These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21417607)

  • 1. A uHPLC-MS mathematical modeling approach to dry powder inhaler single agglomerate analysis.
    Pennington J; Lena J; Medendorp J; Ewing G
    Drug Dev Ind Pharm; 2011 Oct; 37(10):1208-16. PubMed ID: 21417607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a high-throughput UHPLC-MS-based content uniformity method as a tool for assessing dry powder inhalers.
    Medendorp J; Donovan B; Pennington J
    Drug Dev Ind Pharm; 2010 Jul; 36(7):762-72. PubMed ID: 20136489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a directly correlated Raman and uHPLC-MS content uniformity method for dry powder inhalers through statistical design, chemometrics and mathematical modeling.
    Seabrooks L; Canfield N; Pennington J
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1515-23. PubMed ID: 26902663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agglomerate behaviour of fluticasone propionate within dry powder inhaler formulations.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2012 Apr; 80(3):596-603. PubMed ID: 22198291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low powder mass filling of dry powder inhalation formulations.
    Eskandar F; Lejeune M; Edge S
    Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel dry powder inhalation system based on dispersion of lyophilisates.
    Claus S; Schoenbrodt T; Weiler C; Friess W
    Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
    Le VN; Robins E; Flament MP
    Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
    Feddah MR; Brown KF; Gipps EM; Davies NM
    J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
    Tong Z; Yu A; Chan HK; Yang R
    Curr Pharm Des; 2015; 21(27):3966-73. PubMed ID: 26290194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
    Tsong Y; Dong X; Shen M; Lostritto RT
    J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor.
    Nadarassan DK; Assi KH; Chrystyn H
    Eur J Pharm Sci; 2010 Mar; 39(5):348-54. PubMed ID: 20093182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary dispersion formulations: the impact of dispersed powder properties on pressurized metered dose inhaler stability.
    O'Donnell KP; Williams RO
    Drug Dev Ind Pharm; 2013 Mar; 39(3):413-24. PubMed ID: 23216244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DEM analysis of the effect of particle-wall impact on the dispersion performance in carrier-based dry powder inhalers.
    Yang J; Wu CY; Adams M
    Int J Pharm; 2015 Jun; 487(1-2):32-8. PubMed ID: 25845718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A method for the aerodynamic design of dry powder inhalers.
    Ertunç O; Köksoy C; Wachtel H; Delgado A
    Int J Pharm; 2011 Sep; 416(1):25-34. PubMed ID: 21718768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization.
    Heng D; Lee SH; Ng WK; Chan HK; Kwek JW; Tan RB
    Int J Pharm; 2013 Aug; 452(1-2):194-200. PubMed ID: 23680726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Devices for dry powder drug delivery to the lung.
    Berkenfeld K; Lamprecht A; McConville JT
    AAPS PharmSciTech; 2015 Jun; 16(3):479-90. PubMed ID: 25964142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
    de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
    Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dry powder inhalers (DPIs)--a review of device reliability and innovation.
    Islam N; Gladki E
    Int J Pharm; 2008 Aug; 360(1-2):1-11. PubMed ID: 18583072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental observations of dry powder inhaler dose fluidisation.
    Tuley R; Shrimpton J; Jones MD; Price R; Palmer M; Prime D
    Int J Pharm; 2008 Jun; 358(1-2):238-47. PubMed ID: 18457930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Numerical Modelling of Agglomeration and Deagglomeration in Dry Powder Inhalers: A Review.
    Yang J; Wu CY; Adams M
    Curr Pharm Des; 2015; 21(40):5915-22. PubMed ID: 26446462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.